The developments at Holland Capital in 2024 reflect our strong ambitions

Amsterdam/ Düsseldorf, 30th of December 2024 –The developments at Holland Capital in 2024 reflect our strong ambitions. Guided by a focused investment strategy, we continued to actively engage in the high-growth markets of Technology, Healthcare, and Agrifood. Reflecting on a successful year, we completed several key transactions and further strengthened our team.

2024 achievements

Sector focus and an entrepreneurial hands-on approach: With specialized sector teams, we focus on the sectors of Healthcare, Technology, and Agrifood, both within the Growth & Buy-out and Venture & Growth segments. We understand the dynamics and opportunities in these sectors and have an extensive network. Holland Capital is not a passive investor; we work closely with management to define and execute strategies. Where needed, our operational team also contributes hands-on to the realization of specific projects within the company.

Which companies would we like to connect with?

  • Sector: Technology, Healthcare, and Agrifood
  • Positive outlook: Significant growth potential, both autonomous and buy-and-build
  • Growth & Buy-out:
    • Healthy profitability: cash flow from operations (EBITDA) between EUR 1 – 10m
    • Smaller companies: considered as add-on acquisitions for our existing portfolio companies
    • Larger companies: considered together with a co-investor
  • Venture & Growth:
    • Start-ups and scale-ups: EBITDA EUR <1m
    • Cash flow negative (in an accelerated growth scenario)
    • Revenue EUR 0 – 5m

What to expect from us?

  • Flexible approach to transaction structures: We strive to adapt each structure to the needs of the company and its shareholders. Depending on the type of investment, Holland Capital either provides growth capital and/or acquires existing shares. We are flexible regarding the final capital structure: both majority and minority stakes are possible.
  • Deal certainty and an efficient process: Thanks to our sector expertise, we are able to quickly assess a business model and put a fair price on the table. Since the partnership with the entrepreneur and/or the management team is the cornerstone of our investment, we devote above-average attention to ensuring the process is completed efficiently, in the right spirit, and with mutual respect for both parties.
  • Transparency towards advisors: We appreciate it when advisors involve us early in discussions with entrepreneurs and/or management teams. In such cases, we always ensure that the advisor’s interests are well safeguarded throughout the process. The advisor retains the flexibility to decide whether to represent the sell-side or buy-side in a potential transaction.

 

About Holland Capital

Holland Capital has been responsibly and successfully investing in promising Dutch and German SMEs with growth ambitions for over 40 years. The team understands entrepreneurship and fosters an open, sustainable, and professional relationship with the management teams of the invested companies, aiming for mutual growth. With offices in Amsterdam and Düsseldorf, Holland Capital focuses on Healthcare, Technology, and Agrifood-Tech sector.

Holland Venture start nieuw private equity fonds

Amsterdam, 1 juli 2009 - Holland Venture heeft een nieuw private equity fonds van 70 miljoen euro opgezet dat zich richt op groei- en buy-out investeringen in de Benelux. De doelgroep van het fonds bestaat uit bestaande ondernemingen met een ondernemingswaarde tussen...

Verkoop Orthos Europe BV aan Atrium Innovations Inc.

Amsterdam, 22 september 2008 - Holland Venture heeft vandaag haar meerderheidsbelang in Orthos Europe BV verkocht. Orthos Europe BV houdt 100% van de aandelen van AOV Orthomoleculaire Voedingssupplementen BV, een onderneming die hooggedoseerde voedingssupplementen...

Holland Venture verkoopt haar aandelen in INS Group S.A.

Amsterdam, 12 september 2007 - Holland Venture is verheugd om u te kunnen melden dat zij haar aandelen in INS Group, een in België gevestigd netwerk and systemen integrator, aan BT verkocht heeft. Met BT is overeengekomen dat zij 100% van de aandelen in INS Group...

Vacature Investment Analyst Healthcare BO

Investment Manager buy-out HealthcareInvestment Manager buy-out Healthcare Sector: Private Equity en Venture Capital Locatie: Amsterdam Opleidingsniveau: WO Over onze organisatie Holland Capital is een succesvolle participatiemaatschappij welke zich richt op...

CytoSMART haalt 5,2 miljoen euro op voor productinnovatie en groei

CytoSMART haalt 5,2 miljoen euro op voor productinnovatie en groei Eindhoven, 25 maart 2019 - CytoSMART, de Eindhovense ontwikkelaar en fabrikant van digitale microscopen voor het monitoren van celkweekprocessen, ontvangt een groeifinanciering van 5,2 miljoen euro....

Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411

 

Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120

Contact
info@hollandcapital.nl